GSK-2982772

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C20H19N5O3
Molecular Weight	377.3966
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1C2=CC=CC=C2OC[C@H](NC(=O)C3=NNC(CC4=CC=CC=C4)=N3)C1=O

InChI

InChIKey=LYPAFUINURXJSG-AWEZNQCLSA-N

InChI=1S/C20H19N5O3/c1-25-15-9-5-6-10-16(15)28-12-14(20(25)27)21-19(26)18-22-17(23-24-18)11-13-7-3-2-4-8-13/h2-10,14H,11-12H2,1H3,(H,21,26)(H,22,23,24)/t14-/m0/s1

HIDE SMILES / InChI

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Receptor-interacting serine/threonine-protein kinase 1 1 Target ID: Q13546 Gene ID: 8737.0 Gene Symbol: RIPK1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/28151659	Inhibitor 8504

Name

Type

Language

1H-1,2,4-TRIAZOLE-5-CARBOXAMIDE, 3-(PHENYLMETHYL)-N-((3S)-2,3,4,5-TETRAHYDRO-5-METHYL-4-OXO-1,5-BENZOXAZEPIN-3-YL)-

Preferred Name

English

GSK-2982772

Code

English

Code System Code Type Description

CAS

1622848-92-3

Created by admin on Tue Apr 01 17:21:57 GMT 2025 , Edited by admin on Tue Apr 01 17:21:57 GMT 2025

PRIMARY

PUBCHEM

77108121

Created by admin on Tue Apr 01 17:21:57 GMT 2025 , Edited by admin on Tue Apr 01 17:21:57 GMT 2025

PRIMARY

SMS_ID

100000175983

Created by admin on Tue Apr 01 17:21:57 GMT 2025 , Edited by admin on Tue Apr 01 17:21:57 GMT 2025

PRIMARY

FDA UNII

T5W3M0VO9B

Created by admin on Tue Apr 01 17:21:57 GMT 2025 , Edited by admin on Tue Apr 01 17:21:57 GMT 2025

PRIMARY

ACTIVE MOIETY


					T5W3M0VO9B

GSK-2982772